Please login to the form below

Not currently logged in
Email:
Password:

Amylin takes Lilly to court

Amylin files lawsuit against Eli Lilly over alleged breaches of its agreements for the commercialisation of exenatide

Amylin Pharmaceuticals has filed a lawsuit against Eli Lilly and Company in the United States District Court for the Southern District of California, alleging that Lilly is engaging in anticompetitive activity and breaching its agreements to maximise commercialisation of exenatide.

In 2002, Amylin entered an alliance with Lilly for the global development and commercialisation of exenatide, a medicine indicated as a first line treatment for type 2 diabetes that is being marketed as Byetta (exenatide) injection. Exenatide is also the active ingredient in Bydureon (exenatide extended-release for injectable suspension), a once-weekly version under review by the FDA.

Amylin alleges that Lilly is engaging in improper, unlawful and anticompetitive behaviour in the manner in which it plans to implement its recently announced global alliance agreement with Boehringer Ingelheim to jointly develop and commercialise Boehringer's linagliptin product, which will compete with Amylin's exenatide products.

Amylin said: "We are disappointed that we could not resolve this matter amicably and that we were forced to bring legal action to protect our rights, our products and our shareholders. Notwithstanding this litigation, we intend to continue to collaborate with Lilly in the development and commercialisation of exenatide products."

In response, Enrique Conterno, president of Lilly Diabetes, said: "We emphatically reject the allegation that we did not meet our contractual obligations under the Lilly and Amylin alliance.

"Lilly has been and remains fully committed to fulfilling its obligations under its exenatide collaboration agreement with Amylin as well as to complying with all laws and regulations," he added.

17th May 2011

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Evoke Mind+Matter

We are Evoke Mind ‘PLUS’ Matter. The ‘plus’ is important to us because we are all about offering more for...

Latest intelligence

Data security
Concerns about data security are building a strong case for clinical mobility in EMEA
Electronic medical records have transformed the storage of sensitive information but how can the healthcare sector continue to protect patient and staff data?...
Mainimage2
The role of digital health technology tools in supporting medical adherence
How DHT-based digital interventions can help to support patients and improve adherence...
How To Tell A Better Silent Story
They say a picture's worth 1,000 words, which is incredibly helpful when telling a silent story....